Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENULOSE vs CHRONULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.
Treatment of constipation,Portal-systemic encephalopathy (including the prevention and treatment of hepatic coma)
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy)
15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.
10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Terminal elimination half-life approximately 1.5-2.5 hours in adults with normal renal function; may be prolonged to 4-8 hours in patients with renal impairment.
Lactulose is not metabolized in the human small intestine due to the absence of appropriate enzymes. It reaches the colon unchanged and is fermented by colonic bacteria (e.g., Lactobacillus, Bacteroides) into short-chain fatty acids (lactic acid, acetic acid, and formic acid) and gases (hydrogen, carbon dioxide).
Not absorbed systemically; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Primarily renal (as unchanged drug and metabolites): ~40-50% of dose excreted in urine within 24 hours; biliary/fecal elimination accounts for the remainder, with approximately 2-5% recovered in feces as parent compound.
Negligible (<1%), not bound to plasma proteins.
Negligible (<5%), primarily to albumin.
Vd approximately 0.25 L/kg, primarily confined to extracellular fluid.
Approximately 0.25 L/kg; distributes mainly into extracellular fluid.
Oral: very low (<3%) as minimally absorbed; rectal: negligible systemic absorption.
Oral: poorly absorbed; <3% reaches systemic circulation as intact lactulose; the remainder is metabolized by colonic bacteria.
No dose adjustment required for renal impairment; use with caution in severe renal impairment due to electrolyte disturbances.
No dose adjustment required for renal impairment; caution in severe renal impairment due to electrolyte disturbances.
No specific adjustment recommended; monitor for electrolyte imbalances in severe hepatic impairment.
No adjustment needed; used in hepatic encephalopathy at higher doses.
Infants and children: 2.5-10 m L orally once daily, adjusted to produce 2-3 soft stools per day. Maximum 40 m L per day.
Infants: 2.5-5 m L orally once daily; Children 1-5 years: 5-10 m L once daily; Children 6-12 years: 10-15 m L once daily; Adolescents: 15-30 m L once daily; adjust based on response.
Start at lower end of dosing range (15-30 m L daily) due to increased risk of electrolyte disturbances and dehydration. Monitor serum electrolytes.
Start at low end of dosing range (10-15 m L once daily) due to increased risk of electrolyte imbalance and dehydration; monitor fluid/electrolyte status.
None.
None.
Diabetic patients should use with caution due to the sugar content. Prolonged use may lead to electrolyte disturbances (e.g., hypernatremia, hypokalemia). Use with caution in patients with galactosemia or lactose intolerance, as lactulose may contain trace amounts of lactose. Excessive dosing may cause diarrhea and fluid loss.
Electrolyte disturbances (e.g., hypernatremia, hypokalemia) with prolonged use or high doses,Diarrhea may cause fluid and electrolyte loss,Risk of colonic distention or fecal impaction,Use caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (contains galactose and lactose)
Patients with galactosemia (since lactulose contains galactose and may increase galactose levels), intestinal obstruction, or a history of hypersensitivity to lactulose or any component of the formulation.
Patients with galactosemia,Intestinal obstruction,Known hypersensitivity to lactulose
No significant food interactions. May be mixed with fruit juice, water, or milk to mask sweet taste. Lactose-containing products may cause additional gas and bloating in lactose-intolerant patients.
No specific food interactions, but avoid concurrent use with other laxatives. Ensure adequate fluid intake to reduce risk of hypernatremia.
Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with therapeutic doses.
Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not conducted. Based on lack of systemic absorption, risk to fetus is low across all trimesters.
Excreted in breast milk in small amounts; M/P ratio not established. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects.
Lactulose is not absorbed orally; therefore, excretion into breast milk is negligible. Considered compatible with breastfeeding; no M/P ratio available due to lack of systemic absorption.
No pharmacokinetic changes requiring dose adjustment during pregnancy. Standard dosing applies.
No dose adjustment required during pregnancy. Pharmacokinetics of lactulose are unchanged due to lack of systemic absorption. Use standard dosing for constipation (15-30 m L daily, titrated to effect).
ENULOSE (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Monitor for electrolyte disturbances, especially hypernatremia, with prolonged use. In hepatic encephalopathy, titrate to 2-3 soft stools per day. Onset of action for constipation is 24-48 hours. Avoid in patients with galactosemia.
Chronulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Onset of action for constipation is 24-48 hours; monitor for electrolyte disturbances (hypernatremia) with prolonged use. Do not use with other laxatives in acute abdomen. For hepatic encephalopathy, titrate to 2-3 soft stools daily.
Take with or without food. Mix with juice, water, or milk to improve taste.,For constipation: effect may take 24-48 hours. Do not exceed prescribed dose.,For hepatic encephalopathy: maintain 2-3 soft stools daily; adjust dose as directed.,Common side effects include bloating, gas, and cramping. These usually improve with continued use.,Contact your doctor if you experience severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and moisture.
May take 24-48 hours to produce a bowel movement; do not use if you have abdominal pain, nausea, or vomiting.,Mix with fruit juice, milk, or water to improve taste.,Store at room temperature; do not freeze.,Report excessive diarrhea or electrolyte imbalance symptoms (muscle cramps, weakness).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENULOSE vs CHRONULAC, answered by our medical review team.
ENULOSE is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.. CHRONULAC is a Osmotic Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is hydrolyzed by colonic bacteria to form low molecular weight acids (mainly lactic and acetic acid), which osmotically draw water into the colon, softening stools and increasing stool frequency. Additionally, lactulose decreases colonic p H, which traps ammonia (NH3) as ammonium (NH4+), reducing serum ammonia levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENULOSE and CHRONULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENULOSE is: 15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.. The standard adult dose of CHRONULAC is: 10-30 m L orally once daily to twice daily; for acute constipation, 20-30 m L initially; for hepatic encephalopathy, 30-60 m L every 1-2 hours to achieve 2-3 soft stools daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENULOSE and CHRONULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENULOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with th. CHRONULAC is classified as Category C. Lactulose (CHRONULAC) is not absorbed systemically; no teratogenic effects are expected. No adequate and well-controlled studies in pregnant women; animal reproduction studies not . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.